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evasins: therapeutic potential of a 
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1 Geneva Research Centre, Merck Serono S.A., Geneva, Switzerland, 2 Research Department, Novimmune S.A., Plan-les-Ouates, 
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Blood-sucking parasites, such as ticks, remain attached to their hosts for relatively long 
periods of time in order to obtain their blood meal without eliciting an immune response. 
One mechanism used to avoid rejection is the inhibition of the recruitment of immune 
cells, which can be achieved by a class of chemokine-binding proteins (CKBPs) known 
as Evasins. We have identified three distinct Evasins produced by the salivary glands of 
the common brown dog tick, Rhipicephalus sanguineus. They display different selectiv-
ities for chemokines, the first two identified show a narrow selectivity profile, while the 
third has a broader binding spectrum. The Evasins showed efficacy in animal models 
of inflammatory disease. Here, we will discuss the potential of their development for 
therapeutic use, addressing both the advantages and disadvantages that this entails.
Keywords: chemokines, binding proteins, antagonists, pathogens, ticks, protein therapeutics
introdUCtion
The recruitment of immune cells is essential for the establishment of an immune response that, 
if uncontrolled, can lead to an unwanted inflammatory situation. The pharmaceutical industry 
has, for several decades, sought to inhibit excessive leukocyte recruitment by interference with the 
chemokine system, unfortunately with only limited success to date. Therefore, we investigated the 
manner in which pathogens and parasites avoid rejection by an immune response. It has been known 
for some time that pathogens, such as viruses, have pirated many molecules of the mammalian 
immune system, including molecules that either mimic or inhibit chemokines and their receptors to 
subvert the immune system. Among these molecules, there are a number of chemokine-binding pro-
teins (CKBPs) that directly interact with chemokines to inhibit their activity (1). The vast majority of 
CKBPs have been identified in viruses, and these proteins are often able to recognize a large number 
of chemokines. As an example, M3, a protein encoded by the murine gammaherpesvirus-68, binds 
to chemokines from the four different subfamilies (CC, CXC, C, and CX3C) (2), whereas gG (from 
herpes simplex virus) and Crm (encoded by smallpox virus) interact with chemokines from at least 
three subfamilies (3, 4). In 2005, the first eukaryotic CKBP was identified in the worm Schistosoma 
mansoni and was shown to bind promiscuously to some CC chemokines, notably CCL3 and CCL5, 
CXCL8, and CX3CL1 in vitro (5).
Following a report describing anti-CXCL8 activity in the salivary glands of several Ixodid tick 
(or hard tick) species (6), we extended this observation by identifying the molecule responsible 
for this activity. To do this, we first tested the ability of the saliva from the hard tick Rhipicephalus 
sanguineus to inhibit the binding of three chemokines, CCL3, CCL5, and CXCL8 to their receptors, 
and were also able to identify the presence of these molecules in the saliva by surface plasmon 
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resonance (SPR) and mass spectrometry (7). Using cDNA 
 expression libraries constructed from the tick salivary glands, we 
used a cross-linking approach to analyze the proteins secreted 
into culture supernatants after transient expression of pools of 
cDNAs in HEK293 cells. We successfully identified three CKBPs 
that we named the Evasins (7, 8).
CHaraCteristiCs
Evasins have been quite extensively characterized in terms of 
their chemokine-binding profile and inhibitory potency in vitro 
and in  vivo activity. On the one hand, Evasin-1 demonstrated 
the highest specificity as it binds only to three closely related 
chemokines, CCL3, CCL4, and CCL18. On the other hand, 
Evasin-3 recognizes a subset of CXC chemokines, the family of 
the so-called ELR+ chemokines, i.e., CXCL1, -2, -3, -5, -6, and -8. 
Both of these CKBPs efficiently inhibit the activity of their ligands, 
preventing cell migration in vitro. Evasin-4, which was initially 
identified using I125-labeled CCL5 and CCL11 as bait, displayed a 
broader selectivity profile than the other two Evasins, being able 
to interact with at least 18 chemokines, yet it is still highly specific 
as it recognizes only members of the CC subfamily (9). Although 
minor discrepancies were observed between the binding and the 
inhibitory profile of Evasin-4, it blocks the activity of the majority 
of its ligands, including the proinflammatory chemokines CCL3, 
5, 8, and 11.
Based on their binding profile, Evasin-1 and -3 would be 
expected to inhibit the migration of neutrophils in mice, which 
is crucial in the first steps of the immune response. Here, it 
should be noted that one of the major differences in the leuko-
cyte recruitment profiles in the chemokine system is that of the 
neutrophil. In mice, neutrophils express both CCR1 as well as 
CXCR2, which results in the recruitment of this leukocyte by 
both the CCL ligands and the CXCL ligands activating these 
receptors, respectively. Regarding Evasin-4, its ability to prevent 
the interaction of CC chemokines with their receptors may also 
lead to the inhibition of eosinophil recruitment, an essential cel-
lular component of the response against parasites.
Vancova et  al. have reported the presence of anti-CXCL8 
activity and anti-CXCL1 activity in salivary gland extracts from 
males and females of several other species of ticks: Amblyomma 
variegatum, Rhipicephalus appendiculatus, and Dermacentor 
reticulatus, suggesting that Evasin-3-like activity is common 
among metastriate ixodid tick species (10). In a separate study, the 
same group also reported activity against human CXCL8, CCL2, 
CCL3, CCL5, and CCL11 in adult R. appendiculatus ticks (11), 
suggesting that Evasin-1 and Evasin-4 orthologs probably exist 
in this species too. Also in this study, the authors showed that 
anti-chemokine activity differed significantly at different times 
during feeding and also differed between males and females sup-
porting the concept of “mate guarding,” in which males help their 
mates to engorge by controlling their host’s immune response, 
and the possibility that ticks benefit from feeding together in close 
proximity by exploiting molecular individuality. Interestingly, in 
this species, anti-CCL11 activity was high in unfed ticks, initially 
declined, and then increased in both males and females as feeding 
progressed (11).
As previously mentioned, the existence of viral CKBPs 
was reported before the identification of Evasins. However, 
although they probably share similar functions in vivo, several 
differences have been highlighted between these two families 
of CKBP. First, as mentioned above, the large majority of viral 
CKBPs display broad-spectrum chemokine-binding profiles, 
whereas the Evasins are much more selective. It is noteworthy 
that the Evasin-4-binding profile closely mimics that of the 
viral CKBP vCCI. These two CKBPs recognize between 13 and 
18 chemokines, yet are still highly selective in that they bind 
only to CC chemokines (9, 12). Therefore, among CKBPs, they 
form a unique class of chemokine binders with “semi-broad” 
selectivity.
Another key difference between tick and viral CKBPs is the 
size of these proteins. Viral CKBPs are large proteins, which 
might even form dimers as reported for M3 (13). On the contrary, 
Evasins are small proteins of around 80–100 amino acids, indi-
cating that the two partners of the chemokine:Evasin interaction 
have similar sizes.
do eVasins eXist in otHer speCies?
We were intrigued to know whether these molecules formed a 
family of CKBPs in both ticks and in other species, particularly 
man. Blasting their sequences against the human genome, and 
all other mammalian genomes available, did not produce any 
significant hits.
However, at least five putative Evasin-1 and Evasin-3 homologs 
have been identified following in-depth sequence analysis of the R. 
sanguineus sialotranscriptome (14). Expressed sequence tags that 
are Evasin-3-like have been identified in Ixodes scapularis, Ixodes 
ricinus, and Dermacentor andersoni (10), and the sequences of 
potential Evasin homologs have also been identified in Genbank 
for Boophilus microplus and I. scapularis (Power, unpublished 
analysis). At least 18 Evasin homologs have been identified 
for Amblyomma maculatum (15), and Radulovic et  al. recently 
reported a sequence homologous to Evasin-1 in Amblyomma 
americanum (16). Considering there are over 700 Ixodidae spe-
cies, and about 200 soft tick or Argasidae species, with recent 
developments in next generation sequencing and proteomics, it 
is likely that many more homologous sequences will be identified 
in the coming years. Yet whether any of the homologs described 
above encode a CKBP has not yet been confirmed by functional 
analysis.
Even though blasting the primary sequences of the Evasins did 
not reveal homologs in mammals, we hypothesized that proteins 
with similar folds might exist in eukaryotics. While the structures 
of Evasin-1 and Evasin-3 were found to be totally different from 
each other, blasting the PDB database of three-dimensional 
protein structures, once again did not produce any hits. The third 
CKBP, Evasin-4, has a disulfide bridge pattern that aligned with 
that of Evasin-1, indicating that it would probably have the same 
three-dimensional fold (Figure 1) (17), so it was unlikely to pos-
sess a different structural motif. Thus, it appears that while this 
tick species has unique CKBPs, one cannot rule out that other 
ticks, particularly hard ticks that feed for extended periods, will 
have their own unique CKBP(s).
FiGUre 1 | Molecular interactions of evasin-1 and -4 with CCL3. (a) Structure of the complex of Evasin-1 and CCL3 determined by X-ray crystallography.  
(B) Evasin-4 in complex with CCL3 by in silico modeling using (a) (17). (C) Alignment of the primary amino acid sequences of Evasin-1 and -4. Cys residues are 
shown in green and amino acids identified to play a role in chemokine binding are shown in red (17), demonstrating that the selective CHBP, Evasin-1 predominantly 
uses the carboxy terminal region, whereas Evasin-4 that binds many CC chemokines predominantly uses the amino terminal region.
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aCtiVity IN VIVO
The Evasins have all shown efficacy in  vivo in several disease 
models. As predicted from its binding profile, Evasin-1 reduced 
neutrophil recruitment induced by CCL3 in a peritoneal cell 
recruitment assay in a dose-dependent manner (8). This highlights 
one of the anomalies of translating in vivo data from mice to man 
as described above. In humans, CCL3 is not a principal mediator 
of neutrophil recruitment since its receptors CCR1 and CCR5 are 
primarily expressed on monocytes/macrophages, although they 
can be induced, for example, by IFNγ (18). However, in mice, 
CCR1 is highly expressed on neutrophils, resulting in strong 
recruitment in response to CCL3. On the other hand, neutrophil 
recruitment in mice is also mediated by CXCR2 ligands, as it is in 
the human system. Thus, in accordance with its ability to inhibit 
neutrophil infiltration, Evasin-1 showed good efficacy in reduc-
ing the fibrosis, which follows neutrophil infiltration into the lung 
after bleomycin administration, and also reduced the mortality 
observed in this model (19).
Evasin-3 was effective in several neutrophil-dependent 
disease models as expected from its in  vitro selectivity profile, 
showing that it binds and inhibits ELR+ chemokines that bind 
to CXCR2. Again, dose-dependent inhibition of leukocyte 
infiltration into the peritoneal cavity, this time in response to 
CXCL8, was inhibited by Evasin-3. Antigen-induced arthritis 
(AIA), induced by intradermal administration of mouse BSA, 
is highly neutrophil dependent. In AIA, disease symptoms were 
significantly decreased by the administration of Evasin-3. In 
another neutrophil-mediated scenario, ischemic reperfusion 
injury, both Evasin-1 and Evasin-3 were effective, but Evasin-3 
was shown to be more efficacious, indicating that the CXCR2 
ligands play a predominant role in this model. On the contrary, 
only Evasin-1 and not Evasin-3 was effective in inhibiting the first 
wave of dendritic cell recruitment to the site of infection with 
Leishmania major, since it is mediated by neutrophil-secreted 
CCL3 (20). Intriguingly, despite the fact that Evasin-1 has only 
been shown to bind to three chemokines in  vitro, it was able 
to reduce the skin inflammation observed in the D6−/− mice in 
response to 12-O-tetradecanoylphorbol-13-acetate (TPA) (8), a 
model which had previously been shown to depend on several 
inflammatory ligands (21).
Studies with Evasin-4 produced some puzzling observations. 
In line with its broad selectivity profile and inhibitory activity 
against several CC chemokines known to have proinflammatory 
activity, it was shown to be effective in reducing post-infarction 
myocardial injury and remodeling (22) and DSS-induced colitis 
(23), yet Evasin-3 that only binds ELR+ CXC chemokines in vitro 
was also effective in the myocardial injury model. This highlights 
the problem in the translation of agents inhibiting neutrophil-
mediated inflammation in mice to the human setting.
Because of its broad CC chemokine-binding spectrum, 
Evasin-4 was considered the most suitable Evasin for development 
as a possible therapeutic candidate. However, it is well known that 
small proteins have a very short half-life in vivo and are not orally 
available, which means that for chronic indications, they would 
have to be injected with a frequency that is not convenient for 
patients. In order to prolong the serum half-life of therapeutic 
proteins, the strategy of making Fc fusions is often employed. 
Therefore, we created fusions of Evasin-4 with the Fc portion 
of human IgG1, making both N- and C-terminal  versions (9). 
Having characterized the Fc fusion proteins in vitro and selected 
the format that had activity closest to wild-type Evasin-4, we 
compared their activity in a simple disease model, fluorescein 
isothiocyanate (FITC)-induced contact hypersensitivity. While 
Evasin-4 had dose-dependent efficacy in reducing the disease 
symptoms, molar equivalents of the fusion protein were totally 
ineffective (Figure 2).
The negative result obtained with Evasin 4 fused to the 
C-terminal of Fc (Fc-Evasin-4) was unexpected as we predicted 
that the Fc domain would increase the therapeutic potential 
of Evasin-4 and not abrogate its anti-inflammatory activity. In 
the hypersensitivity model, the treatment schedule was based 
FiGUre 2 | FitC-induced contact hypersensitivity. (a) Schematic design of the experiment. (B) Treatment with Evasin-4 reduces ear swelling (n = 5–9 mice per 
group). (C) Treatment with Fc-Evasin-4 does not prevent ear inflammation (n = 8 mice per group). Data are presented as mean ± SEM and were analyzed with 
one-way ANOVA and Dunnett’s post-test. The percentage of ear swelling inhibition is reported for each treatment. ###p < 0.001 compared with sham, **p < 0.01 or 
***p < 0.001 compared with vehicle-treated FITC group, ns not significant.
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on the half-life of the protein, and as Fc-Evasin-4 exhibited a 
much longer half-life than Evasin-4, Evasin-4 was injected twice, 
whereas Fc-Evasin-4 was injected only once, before the challenge 
with FITC. These different treatment schedules may explain the 
lack of activity of Fc-Evasin-4 in comparison to Evasin-4. Our 
current hypothesis is based on the fact that during inflammation, 
a large amount of chemokines is produced and that the adminis-
tration of one single dose of the Fc fusion protein might not have 
been sufficient to saturate the system. 
This was confirmed by the measurement of chemokine levels 
in serum samples from contact hypersensitivity models, which 
demonstrated a significant accumulation of MCP-1 (the murine 
equivalent to CCL2), MIP-1α (equivalent to CCL3), and RANTES 
(equivalent to CCL5) following treatment with Fc-Evasin-4, as 
has been reported for administration of an anti-CCL2 antibody 
(24). Therefore, although the extended half-life of Fc-Evasin-4 
allows it to remain in the circulation for more than 1 week, the 
drug is probably rapidly saturated and no unbound Fc-Evasin-4 
 molecules are available to inhibit newly produced chemokines and 
to reduce inflammation. In the case of Evasin-4, CKBP:chemokine 
complexes are probably more rapidly degraded, preventing their 
accumulation in circulation. Furthermore, the second bolus of 
drug provides an additional amount of free Evasin-4 molecules 
available to inhibit chemokine activity. Therefore, although theo-
retically equimolar, the doses of Evasin-4 and Fc-Evasin-4 used 
are probably not equivalent in vivo. Thus, the Fc fusion would 
only be useful if the chemokine is released and degraded in the 
endosome allowing the fusion protein to recycle back into the 
circulation to pick up more chemokines, necessitating engineer-
ing the Evasin to bind chemokine at pH 7.2 and release it at pH 
6.0, as has been reported for mAbs (25, 26).
tHerapeUtiC potentiaL
A major consideration for the development of protein thera-
peutics is immunogenicity – where the body elicits an immune 
5Bonvin et al. Pathogen-Derived Chemokine-Binding Proteins
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 208
response (production of antibodies) against the therapeutic entity. 
Antibodies against a therapeutic protein may elicit a wide range 
of consequences, from no detectable change to life-threatening 
conditions. One of the main concerns is altered drug safety or 
compromised efficacy. Antibody formation may attenuate the 
efficacy even to the extent that higher doses cannot overcome the 
clinical resistance induced by the antibody response. Deleterious 
effects can occur when antibodies against a therapeutic agent 
cross-react with endogenous proteins. Neutralizing the endog-
enous protein can be particularly dangerous, especially if it is a 
unique protein with non-redundant function. Such was the case 
for erythropoietin a few years ago. An immune response that 
neutralized the activity of both the administered recombinant 
protein Eprex® and that of the endogenous protein in patients 
had dramatic consequences, resulting in an acute anemia called 
pure red-cell aplasia (PRCA) that was fatal in a few patients 
[reviewed in Ref. (27)]. In the case of non-human proteins, espe-
cially those with no homology to any known human protein, this 
type of reaction would not be relevant. Nevertheless, nearly all 
therapeutic proteins – be they native human proteins, monoclo-
nal antibodies, antibody drug conjugates, or fusion proteins – can 
elicit an immune response. Another potential danger of antibody 
formation against therapeutic proteins is the elicitation of immu-
noglobulin (Ig) E-mediated hypersensitivity reactions ranging 
from local skin reactions to more severe systemic reactions such 
as anaphylaxis. However, cases of anaphylaxis have been seen 
with almost every substance administered to man, ranging from 
peanuts to recombinant interferon-β, but fortunately are not 
common.
Nevertheless, there are already examples of non-human pro-
teins in the clinic. Hirudin, a small protein produced by leeches, 
is an inhibitor of thrombin and is used extensively for the 
retreatment of heparin-induced thrombocytopenia for patients 
undergoing hip replacement surgery (28). A second example is 
the GLP-1 receptor agonist exenatide (synthetic exendin-4), a 39 
amino acid peptide, marketed as Byetta®, which was originally 
identified in the salivary secretions of a poisonous lizard known 
as the Gila monster (Heloderma suspectum). Exenatide was 
developed as a first-in-class type 2 diabetes therapy (29). In a 
recent report, it was shown that low-titer anti-exenatide antibod-
ies were common with exenatide treatment but had no apparent 
effect on efficacy. Higher titer antibodies were less common, and 
increasing antibody titer was associated with reduced average 
efficacy, but other than injection-site reactions there were no 
safety issues (30).
A number of factors are now known to influence the immuno-
genicity of therapeutic proteins, but in general, the less “human” 
a protein is, the more likely it is to elicit an immune response, 
particularly following repeated administrations. However, pre-
dicting immunogenicity remains a subject of much debate. We 
used both proprietary (Antipred) and publicly available software 
(TEPITOPE) for in  silico prediction of potential CD4+ T-cell 
epitopes in the Evasins. Interestingly, interferon-β, one of the most 
widely used treatments for multiple sclerosis, was predicted to 
contain more antigenic sites than the Evasins (unpublished data).
It should also be noted that the Evasins produced by the 
tick are highly glycosylated proteins. Their apparent molecular 
weights as estimated by SDS-PAGE analysis during their expres-
sion cloning was about five times their actual protein mass. 
This could be hypothesized to render them less susceptible to 
a host immune response. The counter argument to their status 
of immune-silent is that they are injected into the host in saliva 
containing a plethora of other proteins, which could equally 
play a role in preventing an immune reaction. This is obviously 
not the case for a therapeutic protein, where in fact the route 
of administration and relatively large amounts that would be 
administered systemically (compared to the miniscule amounts 
injected locally in tick saliva) would be influential on the ensuing 
immunogenicity.
In view of the potential of the Evasins as therapeutic modalities, 
we produced Evasin-3 and -4 as Fc fusion proteins. This was to 
counteract their rapid elimination as is the case for all small pro-
teins. Both fusion proteins retained neutralizing activity in vitro 
comparable to the wild-type proteins. However, surprisingly, 
Evasin-4 lost its neutralizing activity when administered as an Fc 
fusion. The WT protein showed dose-related activity in inhibiting 
the clinical symptoms in a contact hypersensitivity model, but 
administration of equivalent molar amounts of the Fc fusion had 
no effect whatsoever. The reason for this remains unexplained, 
but these results prompt us to wonder whether simultaneous 
inhibition of chemokines with a multispecific chemokine-
binding protein may be an efficient strategy to clinically improve 
chemokine-driven diseases. As pan-specific chemokine inhibi-
tors bind to multiple targets, and as the amount of chemokines 
present in the body may be very large, due to immobilization on 
cell surfaces, as well as to rapid turnover and production rates, 
multispecific inhibitors might be saturated in vivo, and very high 
doses may be required to observe an anti-inflammatory activity. 
This hypothesis may also explain the lack of long-term efficacy 
reported with the fusion protein vCCI-Fc (31). As discussed 
above, a solution could be the engineering of the CKBPs to render 
them pH dependent. Alternatively, if simultaneous inhibition of 
several chemokines is required, a more successful strategy may 
be the broad inhibition of chemokine-induced cell migration 
without direct interaction with chemokines or their receptors. 
This strategy is exemplified by the broad-spectrum chemokine 
inhibitors known as somatotaxins, such as NR58-3.14.3, which 
is effective in a range of inflammatory disease models, including 
atherosclerosis and graft-versus-host disease (32–34). Another 
example of broad-spectrum chemokine inhibition would be by 
interfering with chemokine signaling as demonstrated by PI3K 
inhibitors. These results suggest that indirect interference with 
cell migration may be a promising strategy to prevent excessive 
recruitment to inflamed sites.
It is clear from the above examples that certain pathologies 
may be driven by the action of several chemokines acting on 
distinct receptors, thus arguing that the use of broad-spectrum 
chemokine antagonists or at least multispecific antagonists would 
be beneficial. However, a recent report demonstrating biased ago-
nism (35) has provided rationale for targeting individual ligands 
with biologicals, such as mAbs, to avoid off-target effects. A good 
example is the receptor CXCR3, whose ligands CXL10 and 
CXCL11 play opposing roles –  the former having a proinflam-
matory activity while the latter is anti-inflammatory (36). To date, 
CCR2/CCR5 CCR2 CCR1 CX3CR1 Evasin 4
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FiGUre 3 | inhibition of synovial fluid-induced monocyte recruitment by selective chemokine receptor inhibitors and evasin-4.
6
Bonvin et al. Pathogen-Derived Chemokine-Binding Proteins
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 208
most of the therapeutic approaches taken by the pharmaceutical 
industry have been to inhibit individual chemokine receptors. 
Nevertheless, there are still gaps in our understanding of their pre-
cise roles. An interesting example is CCR2 that binds several CC 
chemokines: CCL7, CCL8, and CCL14, which also bind to other 
receptors, but the CCL2/CCR2 interaction is non-redundant. 
CCR2 has been targeted in three separate clinical trials without 
much success. Is this due to a problem with the target or the drug? 
The importance of the CCL2/CCR2 interaction in monocyte 
recruitment is compelling, yet animal models suggest that CCR1 
may also play role (37). How does this relate to monocyte recruit-
ment in human disease? In a recent in vitro study, we looked at 
the ability of specific chemokine receptor antagonists and Evasins 
to block monocyte chemotaxis in response to synovial fluid har-
vested from six rheumatoid arthritis patients (Proudfoot et  al., 
unpublished data).1 We observed that only Evasin-4 could inhibit 
monocyte migration in all samples (Figure  3). In this system, 
Evasin-4 acts as a soluble chemokine receptor with specificity 
for multiple monocyte-directed ligands, providing a much more 
simple approach to chemokine antagonism than targeting one, 
two, or even multiple chemokine receptors with small-molecule 
antagonists or antibodies.
Thus, the Evasins present therapeutic potential in patholo-
gies where several chemokines are involved. However, there are 
certain aspects that must be addressed for future development 
of these molecules. In view of the observed lack of activity with 
the Evasin-Fc fusion, treatment of acute indications, where short 
half-life is not a problem, would be first choice. Moreover, the 
administration of such proteins for an acute regimen would 
circumvent the potential issues of immunogenicity. The develop-
ment of the Evasins for more chronic diseases would require opti-
mization of the potential biologic modality, for example, half-life 
extension. Production of a pH-dependent chemokine-binding 
1 A. Proudfoot, C. Gabay, A. Garin.  2016, unpublished work
molecule could also solve the problem of the large amount of tar-
get protein(s) to be neutralized. With their small size and unique 
structure, Evasins are also very attractive targets for protein 
engineering to introduce exquisite specificity, as more and more 
information becomes available on the role of specific chemokines 
in human disease. However, we believe that future directions in 
the search for novel innovative approaches to the treatment of 
inflammatory diseases should include the study of how nature 
deals with the immune system – there is still a lot to be learnt from 
pathogens and parasites that have evolved elegant mechanisms to 
avoid rejection by their hosts.
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